Bradford, H. Alexander
January 1964
Angiology;Jan1964, Vol. 15 Issue 1, p35
Academic Journal
Sixteen years experience with a closely followed group of patients suffering from various thromboembolic diseases tends to support the value of this type of protective therapy. With a maintained range of prothrombin activity from 20 per cent to 30 per cent, no great problems were encountered in cooperative, properly indoctrinated patients. Hemorrhagic complications within these limits were infrequent and generally limited. Scrutiny of instances of bleeding disclosed a number of factors as complications in treatment. The suggestion arises that smoother drug absorption may occur with warfarin sodium than with bishydroxycoumarin. Although this was not a controlled study, the benefit of this therapy was notable in patients who were followed for longer intervals, especially in specific instances. This deterrent value was suggested when there was a sustained abrupt remission of thromboembolic episodes after treatment was begun and when patients exhibited resumption of thromboembolism when treatment was stopped. Recurrence of thromboembolic complications, while not prevented, tended to be fewer and milder in nature.


Related Articles

  • Anticoagulant 'as good as warfarin' in VTE prevention. Moberly, Tom // GP: General Practitioner;12/11/2009, p10 

    The article reports on a study according to which dabigatran is equally safe and effective as warfarin in preventing recurrent venous thromboembolism (VTE). Studies have shown that patients treated with dabigatran do not need their coagulation levels monitored as dabigatran does not interact...

  • Conventional-intensity was more effective than low-intensity warfarin therapy for preventing recurrent venous thromboembolism: COMMENTARY. Beyth, Rebecca // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p37 

    The article comments on a study conducted to analyze effectiveness of conventional-intensity over low-intensity warfarin therapy for preventing recurrent venous (VTE) thromboembolism. In patients with unprovoked VTE who have received 3 months of vitamin K antagonists (VKAs) with a target...

  • Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios. Schulman, Sam; Parpia, Sameer; Stewart, Clare; Rudd-Scott, Lisa; Julian, Jim A.; Levine, Mark // Annals of Internal Medicine;11/15/2011, Vol. 155 Issue 10, p653 

    Background: Guidelines recommend that patients receiving warfarin undergo international normalized ratio (INR) monitoring every 4 weeks. Objective: To investigate whether assessment of warfarin dosing every 12 weeks is as safe as assessment every 4 weeks. Design: Noninferiority randomized trial....

  • Managing Outpatient Anticoagulation. Jackson, Carol Mackenzie // Clinician Reviews;Feb2008, Vol. 18 Issue 2, p28 

    The article offers a practical guide to managing outpatient anticoagulation therapy (OACT), primarily for patients taking warfarin. Such therapy may be aimed toward primary or secondary prevention of thromboembolism. The three-part therapeutic process involves categorizing the patient...

  • Heparin prevents recurrent VTE in cancer patients. Clenney, Timothy L.; Viera, Anthony J. // Journal of Family Practice;Nov2003, Vol. 52 Issue 11, p843 

    In a study of 676 adults with active cancer and newly diagnosed venous thromboembolism (VTE) it was found that the use of low-molecular-weight heparin is an effective approach for the prevention of VTE. The subjects were divided into two groups, the heparin-dalteparin and warfarin groups....

  • Bridging increases bleeding risk during warfarin interruption.  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p9 

    The article presents a study which reveals that bridge therapy using short-acting anticoagulant can increase the risk of bleeding during warfarin interruption in patients with a history of venous thromboembolism (VTE) undergoing invasive diagnostic or surgical procedures.

  • The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin. Ucar, Mahmut; Alagozlu, Hakan; Sahin, Safak; Ozdemir, Ozturk // Medicinski Glasnik;Feb2013, Vol. 10 Issue 1, p50 

    Aim Oral anticoagulants are the most common used substance for treatment and prophylaxis of warfarin venous and arterial thromboembolic disorders in the world. Therapeutic index of warfarin is narrow. CYP2C9 is a hepatic microsomal enzyme and has a primary role in metabolism of warfarin and...

  • Extended Treatment of VTE with Dabigatran vs Warfarin. Kuritzky, Louis // Neurology Alert;May2013 Clinical Briefs in Primary Care, p9 

    The article discusses a study by S. Schulman and colleagues, published in a 2013 issue of the "New England Journal of Medicine," which found that dabigatran was noninferior to warfarin in preventing recurrent uncomplicated venous thromboembolism (VTE).

  • Dalteparin alternative in VTE prevention for patients with cancer.  // PharmacoEconomics & Outcomes News;7/1/2006, Issue 506, p1 

    The article discusses research being done on the use of dalteparin sodium for the prevention of recurrent venous thromboembolism (VTE) in cancer patients. It references a study by G. Dranitsaris et al published in a 2006 issue of "Pharmacoeconomics." A health resource utilisation data was used...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics